SR One

SR One is a transatlantic biotechnology venture capital firm dedicated to partnering with founders and entrepreneurs to translate innovative science into transformative medicines. The firm employs a "back-and-build" investment approach, focusing on companies with strong underlying fundamentals, clearly defined development pathways, and novel strategies for addressing diseases. Their mission is to reimagine today's scientific breakthroughs for tomorrow's medical solutions, actively collaborating to build value through various inflection points in a company's growth.

Originally established in 1985 as the corporate venture arm of GlaxoSmithKline (GSK), SR One completed its spin-out to become an independent investment firm in late 2020. This transition marked a significant milestone, allowing the firm greater flexibility and a broader investor base. Following the spin-out, SR One closed its first independent fund at $500 million, which was the largest first-time VC fund focused on U.S. and European biotech startups in 2020. Subsequently, the firm closed its second fund at over $600 million, bringing its total assets under management to more than $1.5 billion.

SR One has invested in a diverse portfolio of biotechnology companies across various therapeutic areas, including oncology, immunology, rare diseases, and cardiometabolic conditions. Notable investments and portfolio companies include CRISPR Therapeutics, Principia Biopharma (acquired by Sanofi), Turning Point Therapeutics, Progyny, Nkarta Therapeutics, Arcellx, Odyssey Therapeutics, Rezo Therapeutics, Pandion Therapeutics (acquired by Merck), Design Therapeutics, VeraDermics, and Zenas BioPharma. The firm's investments span clinical and preclinical stages, aiming to address significant unmet medical needs.

The firm's transatlantic team is strategically located in key biotechnology hubs on the West Coast, USA (Redwood City, CA) and London, UK, with an additional presence in the Philadelphia area. This geographic footprint enables SR One to access high-quality science and opportunities across regions, providing real-time business support and regional expertise to its portfolio companies. The leadership team, including CEO and Managing Partner Simeon George, brings extensive experience in biotech investments, company creation, and operational support, with backgrounds in management consulting, investment banking, and pharmaceutical development.